Celldex Ends Late-Stage Vaccine Study For Rare Brain Cancer

Celldex Ends Late-Stage Vaccine Study For Rare Brain Cancer

Celldex Therapeutics Inc. has suspended its late-stage study for a brain cancer vaccine after an analysis found that the vaccine was not any more effective than standard chemotherapy. By Cheri … The Data Safety and Monitoring Board's analysis

(Visited 1 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.